BACKGROUND: The epidemic of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has had a disproportionate impact on patients with human immunodeficiency virus (HIV). METHODS: We evaluated CA-MRSA colonization burden (number of colonized sites per total number sampled) among HIV-infected and HIV-negative inpatients within 72 hours of hospitalization. From March 2011 through April 2012, we obtained cultures from nasal and extranasal sites (throat, axilla, inguinal, perirectal, and chronic wound if present) and collected risk factor data. RESULTS: Of 745 patients (374 HIV-infected, 371 HIV-negative), 15.7% were colonized with CA-MRSA at any site: 20% of HIV and 11% of HIV-negative patients (relative prevalence=1.8, P=.002). HIV-infected patients had a higher prevalence of nasal, extranasal, and exclusive extranasal colonization as well as higher colonization burden. Perirectal and inguinal areas were the extranasal sites most frequently colonized, and 38.5% of colonized patients had exclusive extranasal colonization. Seventy-three percent of isolates were identified as USA300. Among HIV-infected patients, male sex, younger age, and recent incarceration were positively associated whereas Hispanic ethnicity was negatively associated with higher colonization burden. Among HIV-negative patients, temporary housing (homeless, shelter, or substance abuse center) was the only factor associated with higher colonization burden. Predictors of USA300 included HIV, younger age, illicit drug use, and male sex; all but 1 colonized individual with current or recent incarceration carried USA300. CONCLUSIONS: HIV-infected patients were more likely to have a higher CA-MRSA colonization burden and carry USA300. In certain populations, enhanced community and outpatient-based infection control strategies may be needed to prevent CA-MRSA cross-transmission and infection.
BACKGROUND: The epidemic of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has had a disproportionate impact on patients with human immunodeficiency virus (HIV). METHODS: We evaluated CA-MRSA colonization burden (number of colonized sites per total number sampled) among HIV-infected and HIV-negative inpatients within 72 hours of hospitalization. From March 2011 through April 2012, we obtained cultures from nasal and extranasal sites (throat, axilla, inguinal, perirectal, and chronic wound if present) and collected risk factor data. RESULTS: Of 745 patients (374 HIV-infected, 371 HIV-negative), 15.7% were colonized with CA-MRSA at any site: 20% of HIV and 11% of HIV-negative patients (relative prevalence=1.8, P=.002). HIV-infectedpatients had a higher prevalence of nasal, extranasal, and exclusive extranasal colonization as well as higher colonization burden. Perirectal and inguinal areas were the extranasal sites most frequently colonized, and 38.5% of colonized patients had exclusive extranasal colonization. Seventy-three percent of isolates were identified as USA300. Among HIV-infectedpatients, male sex, younger age, and recent incarceration were positively associated whereas Hispanic ethnicity was negatively associated with higher colonization burden. Among HIV-negative patients, temporary housing (homeless, shelter, or substance abuse center) was the only factor associated with higher colonization burden. Predictors of USA300 included HIV, younger age, illicit drug use, and male sex; all but 1 colonized individual with current or recent incarceration carried USA300. CONCLUSIONS:HIV-infectedpatients were more likely to have a higher CA-MRSA colonization burden and carry USA300. In certain populations, enhanced community and outpatient-based infection control strategies may be needed to prevent CA-MRSA cross-transmission and infection.
Authors: Fred C Tenover; Linda K McDougal; Richard V Goering; George Killgore; Steven J Projan; Jean B Patel; Paul M Dunman Journal: J Clin Microbiol Date: 2006-01 Impact factor: 5.948
Authors: Scott K Fridkin; Jeffrey C Hageman; Melissa Morrison; Laurie Thomson Sanza; Kathryn Como-Sabetti; John A Jernigan; Kathleen Harriman; Lee H Harrison; Ruth Lynfield; Monica M Farley Journal: N Engl J Med Date: 2005-04-07 Impact factor: 91.245
Authors: Jeffrey A Rihn; Klara Posfay-Barbe; Christopher D Harner; Andy Macurak; Adrianne Farley; Kathy Greenawalt; Marian G Michaels Journal: Pediatr Infect Dis J Date: 2005-09 Impact factor: 2.129
Authors: Sophia V Kazakova; Jeffrey C Hageman; Matthew Matava; Arjun Srinivasan; Larry Phelan; Bernard Garfinkel; Thomas Boo; Sigrid McAllister; Jim Anderson; Bette Jensen; Doug Dodson; David Lonsway; Linda K McDougal; Matthew Arduino; Victoria J Fraser; George Killgore; Fred C Tenover; Sara Cody; Daniel B Jernigan Journal: N Engl J Med Date: 2005-02-03 Impact factor: 91.245
Authors: Michael W Ellis; Duane R Hospenthal; David P Dooley; Paula J Gray; Clinton K Murray Journal: Clin Infect Dis Date: 2004-09-02 Impact factor: 9.079
Authors: Craig E Zinderman; Byron Conner; Mark A Malakooti; James E LaMar; Adam Armstrong; Bruce K Bohnker Journal: Emerg Infect Dis Date: 2004-05 Impact factor: 6.883
Authors: Kyle J Popovich; Evan Snitkin; Stefan J Green; Alla Aroutcheva; Mary K Hayden; Bala Hota; Robert A Weinstein Journal: Clin Infect Dis Date: 2015-09-07 Impact factor: 9.079
Authors: James A McKinnell; Loren G Miller; Samantha J Eells; Eric Cui; Susan S Huang Journal: Infect Control Hosp Epidemiol Date: 2013-08-19 Impact factor: 3.254
Authors: Jason E Farley; Matthew J Hayat; Paul L Sacamano; Tracy Ross; Karen Carroll Journal: Am J Infect Control Date: 2015-02-14 Impact factor: 2.918
Authors: Kyle J Popovich; Evan S Snitkin; Bala Hota; Stefan J Green; Ali Pirani; Alla Aroutcheva; Robert A Weinstein Journal: J Infect Dis Date: 2017-06-01 Impact factor: 5.226
Authors: Kyle J Popovich; Alla Aroutcheva; Bala Hota; Kathleen G Beavis; Mary K Hayden; Robert A Weinstein Journal: Infect Control Hosp Epidemiol Date: 2014-07-25 Impact factor: 3.254
Authors: Angela A Aidala; Michael G Wilson; Virginia Shubert; David Gogolishvili; Jason Globerman; Sergio Rueda; Anne K Bozack; Maria Caban; Sean B Rourke Journal: Am J Public Health Date: 2015-11-12 Impact factor: 9.308